glp 1 agonists alzheimer's Antidiabetic GLP-1 Receptor Have Neuroprotective Properties in Experimental Animal Models of Disease Potential Role of Glucagon-like Peptide-1

Exp Clin Endocrinol Amp Diabetes (2022) 130:35867

Significant data emerged in this regard from the previously discussed trial by Armstrong et al

60 In a meta-analysis by Shi et al., GLP-1RAs significantly reduced AF events compared to metformin, sulfonylurea, insulin and non-sulfonylurea in patients with T2D and were associated with better outcomes compared to other medications

It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating

doi: 10.1007/s40120-022-00350-y [DOI] [PMC free article] [PubMed] [Google Scholar] 34

Other findings included: Gallbladder issues (especially with rapid weight loss) Pancreatitis (rare, with unclear causality) Thyroid C-cell hyperplasia (in animals, not seen in humans) Lean mass lossup to 40% of weight lost may be muscle in older adults None of these derailed regulatory approvals